

---

---

# Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening

Nicolas Tournier<sup>1,2</sup>, Héric Valette<sup>1</sup>, Marie-Anne Peyronneau<sup>1</sup>, Wadad Saba<sup>1</sup>, Sébastien Goutal<sup>1</sup>, Bertrand Kuhnast<sup>1</sup>, Frédéric Dollé<sup>1</sup>, Jean-Michel Scherrmann<sup>2,3</sup>, Salvatore Cisternino<sup>2,3</sup>, and Michel Bottlaender<sup>1</sup>

<sup>1</sup>CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France; <sup>2</sup>Assistance Publique-Hôpitaux de Paris, Paris, France; and <sup>3</sup>INSERM U705, CNRS UMR8206-Universités Paris Descartes et Paris Diderot, Paris, France

---

Radiolabeled compounds used for brain imaging with PET must readily cross the blood-brain barrier (BBB) to reach their target. Efflux transporters at the BBB—P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP)—could limit their uptake by the brain. **Methods:** We developed and validated an in vitro model using MDCKII cells transfected with human multidrug resistance (*MDR1*) or *BCRP* genes and assessed the transport of selected PET ligands by the concentration equilibrium technique. The tested compounds included befloxaceton, (*R,S*)-CGP-12177, clorgyline, *R*-(-)-deprenyl, diprenorphine, DPA-714, fallypride, flumazenil, 2-fluoro-A-85380, LBT-999, loperamide, *p*-MPPF, PE2I, Pittsburgh compound B (PIB), (*R,S*)-PK11195, raclopride, *R*-(+)-verapamil, and WAY-100635. The assays were performed using the nonradioactive form of each compound (ultraviolet high-performance liquid chromatography analysis) and, when available, the <sup>18</sup>F-labeled analogs ( $\gamma$ -counting). **Results:** Befloxaceton appeared to be transported solely by BCRP. Loperamide, verapamil, and diprenorphine were the only P-gp substrates. Other ligands were transported by neither P-gp nor BCRP. **Conclusion:** The present method can readily be used to screen new-compound transport by P-gp or BCRP, even before any radiolabeling. Compounds that were previously thought to be transported by P-gp in rodents, such as *p*-MPPF, WAY-100635, and flumazenil, cannot be considered substrates of human P-gp. The impact of BCRP and P-gp at the BBB on the transport of befloxaceton and diprenorphine in vivo remains to be evaluated with PET.

**Key Words:** P-glycoprotein; breast cancer resistance protein; blood-brain barrier; positron emission tomography; radiotracers; ABC proteins

**J Nucl Med 2011; 52:415–423**

DOI: 10.2967/jnumed.110.079608

---

All drugs that act on the central nervous system must cross the blood-brain barrier (BBB) to reach the brain pa-

renchyma. It is now well established that there are several carrier-mediated systems that interact with many xenobiotics at the BBB (1). These BBB transporters can affect the rate and extent of central nervous system drug distribution and influence their pharmacodynamics. Similarly, the way in which central nervous system radiotracers interact with BBB transporters may produce differences in their distribution between species or even individuals.

The adenosine triphosphate-binding cassette (ABC) efflux transporters—P-glycoprotein (P-gp: ABCB1, multidrug resistance [MDR1]) and breast cancer resistance protein (BCRP: ABCG2)—are now considered to influence the distribution of many structurally unrelated substrates within the central nervous system (1). Some genetic variants of the *ABCB1* and *ABCG2* genes are believed to influence the pharmacokinetics of their substrates, as reported for the opiates methadone (2) and fentanyl (3), which are putative P-gp substrates, whose distributions may be influenced by P-gp activity (4). Regional variations in the function of P-gp at the BBB of individuals with neurologic disorders such as epilepsy, Parkinson disease, and Alzheimer disease (1,5) may occur. These variations may account for some variability in brain imaging: several PET ligands have been identified as P-gp substrates, and their crossing of the BBB is therefore controlled by an active efflux kinetic process (6). Some of these drugs, such as *R*-(+)-verapamil, loperamide, and its nonopioid derivative *N*-desmethyl-loperamide, have been specifically used in PET studies to determine the physiologic impact of P-gp (5).

The U.S. Food and Drug Administration has now made it mandatory that the P-gp substrate status of licensed drugs be evaluated (7). Variations in the transport of a drug and potential drug-drug interactions at the BBB can significantly influence the distribution of a drug. Most studies on the carrier-mediated transport of radiotracers across the BBB are performed on rodents using chemical inhibition or physical disruption of the P-gp or Bcrp transporter genes (8). However, some differences in the spectra of ABC substrates of the human and rodent isoforms of P-gp indicate that models of human ABCs should be used (9,10). A few studies have been done on humans, but they

---

Received May 28, 2010; revision accepted Aug. 6, 2010.

For correspondence or reprints contact: Nicolas Tournier, CEA, I2BM, Service Hospitalier Frédéric Joliot, 4, place du Général Leclerc, F-91401 Orsay, France.

E-mail: nicolas.tournier@cea.fr

COPYRIGHT © 2011 by the Society of Nuclear Medicine, Inc.

require expensive, time-consuming experimental protocols using cyclosporine A or newer-generation P-gp inhibitors (11,12). These technical issues readily explain why the interactions between clinically useful PET radiotracers and human P-gp are poorly documented. BCRP was discovered more recently, and its impact at the human BBB remains to be assessed (13).

The present study characterized the transport by human P-gp and human BCRP of several ligands that are routinely radiolabeled for PET. These compounds were tested using both their nonradioactive form and, when available, their  $^{18}\text{F}$ -radiolabeled analogs in a concentration equilibrium assay using Madin-Darby canine kidney II (MDCKII) cells transfected with the *hMDR1* or *hBCRP* genes.

## MATERIALS AND METHODS


### Chemicals

The chemical structures of tested compounds are presented in Figure 1. Befloxatone, *R*-(-)-deprenyl, and (*R,S*)-PK11195 ((*R,S*)-*N*-methyl-*N*-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide) were gifts from Sanofi-Aventis, (*R,S*)-CGP-12177 (4-[3-[(1,1-dimethylethyl)amino]2-hydroxypropoxy]-1,3-dihydro-2*H*-benzimidazol-2-one hydrochloride) was from Ciba, flumazenil from Roche, and PSC833 (valsopodar) from Novartis. Clorgyline, funitremorgin C, loperamide, *p*-MPPF (4-(2'-methoxyphenyl)-1-

[2'-[*N*-(2"-pyridinyl)-*p*-flourobenzamido]ethyl]piperazine), prazosin, raclopride, *R*-(+)-verapamil, and WAY-100635 (*N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(2-pyridyl)cyclohexanecarboxamide) were all purchased from Sigma-Aldrich; diprenorphine from Reckitt and Colman; and fallypride (*N*-[(2*S*)-1-(2-propenyl)-2-pyrrolidinyl]methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide) and Pittsburgh compound B (PIB) from ABX GmbH. DPA-714 (*N,N*-diethyl-2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5- $\alpha$ ]pyrimidin-3-yl)acetamide) (14), 2-fluoro-A-85380 (2-fluoro-3-[2(*S*)-2-azetidylmethoxy]pyridine) (15), LBT-999 (8-((*E*)-4-fluoro-but-2-enyl)-3 $\beta$ -*p*-tolyl-8-aza-bicyclo[3.2.1]octane-2 $\beta$ -carboxylic acid methyl ester) (16), and PE2I ((*E*)-*N*-(3-iodoprop-2-enyl)-2 $\beta$ -carbomethoxy-3 $\beta$ -(4'-methylphenyl) nortropine) (17) were synthesized in-house according to published methods.

### Radiochemicals

$^3\text{H}$ -prazosin and  $^3\text{H}$ -raclopride were purchased from Perkin-Elmer. Over 99% radiochemically pure  $^{18}\text{F}$ -labeled DPA-714, fallypride, 2-fluoro-A-85380, and LBT-999 were prepared from cyclotron-produced  $^{18}\text{F}$ -fluoride (Cyclone-18/9 cyclotron; IBA) on the basis of already published standard conditions ( $^{18}\text{F}$ -DPA-714 (14),  $^{18}\text{F}$ -fallypride (18), 2- $^{18}\text{F}$ -fluoro-A-85380 (15), and  $^{18}\text{F}$ -LBT-999 (16)) using a commercially available TRACERLab FX-FN synthesizer (GE Healthcare). All preparations included a final high-performance liquid chromatography (HPLC) purification (performed on semipreparative X-Terra RP18 [Waters],



**FIGURE 1.** Chemical structure of PET ligands tested on concentration equilibrium assay using MDCKII-MDR1 and -BCRP cells.

SunFire C-18 [Waters], ZorbaxSB [Hewlett Packard], and Symmetry C18 [Waters] HPLC columns, respectively) and a formulation for intravenous injection (using a SepPakPlus C-18 cartridge [Waters]-based removal of the HPLC solvents). Quality controls were performed on an aliquot of the ready-to-inject preparations, in compliance with our in-house quality control and quality assurance specifications.

### Cell Culture

MDCKII-hMDR1 and MDCKII-human BCRP cells were generous gifts from Alfred Schinkel (National Cancer Institute, The Netherlands). They were grown in Dulbecco modified Eagle medium (Invitrogen) containing 10% heat-inactivated fetal bovine serum, glutamine, a 100 U/mL concentration of penicillin, and a 100 µg/mL concentration of streptomycin (Invitrogen) at 37°C in a humidified atmosphere of 95% air/5% CO<sub>2</sub> and passaged twice a week. The presence of transporters was assessed by Western blotting of whole-cell lysates (19).

### Bidirectional Transport Study

Bidirectional transport was studied as previously described (19,20). Briefly, cells were seeded ( $3 \times 10^5$  cells/cm<sup>2</sup>) on 12-well Corning Costar Transwell polycarbonate membranes (ATGC) and grown to confluence (3 d). Preliminary checks, including Lucifer yellow permeation (marker of the paracellular route) and transepithelial resistance measurement, indicated that these culture conditions were optimal for producing a confluent monolayer (19). Transepithelial resistance was determined using a Millicell ERS ohm-meter (Millipore) before and after incubation to ensure monolayer integrity. Monolayers with a transepithelial resistance of less than 200 Ω·cm<sup>2</sup> were discarded. On the day of the experiment, the culture medium was replaced by Hanks balanced salt solution buffer containing CaCl<sub>2</sub> and MgCl<sub>2</sub> supplemented with 1 mM pyruvate and 10 mM *N*-2-hydroxyethylpiperazine-*N*-2-ethanesulfonic acid (Invitrogen) in both the apical compartment (compartment A, 0.5

mL) and the basolateral compartment (compartment B, 1.5 mL), with or without a transport inhibitor, and preincubated for 1 h. P-gp was inhibited with 5 µM PSC833, and BCRP with 10 µM fumitremorgin C. Permeation in both directions, apical to basolateral (A to B) and basolateral to apical (B to A), was measured. Transport medium containing the compound to be tested, with or without specific inhibitor, was then placed in the donor compartment. *p*-MPPF (10 µM) was used to ensure that the concentration in the opposite compartment was above the limit of quantification of the analytic procedure. Monolayer efflux was stopped after 90 min. The concentrations of tested compound in the receiver compartment were determined. The apparent permeability coefficient  $P_{app}$  (nm·s<sup>-1</sup>) is determined from the amount of compound cumulating in the receiver compartment over time ( $dQ_r/dt$ ; µmol·s<sup>-1</sup>) according to the following equation:

$$P_{app}(\text{nm} \cdot \text{s}^{-1}) = [(dQ_r/dt)/(A \times C_0)] \times 10^7,$$

where  $A$  is the area of the cell monolayer (cm<sup>2</sup>) and  $C_0$  (µmol·cm<sup>-3</sup>) is the initial concentration of the dosing solution at time  $t = 0$ , determined by the analytic method. Data are usually presented as average  $P_{app}$  (nm·s<sup>-1</sup>) ± SD from 6–9 monolayers. Efflux ratio was determined by dividing the mean  $P_{app}$  (B to A) by the mean  $P_{app}$  (A to B). Involvement of a transport-mediated efflux was confirmed when the efflux ratio was more than 1.5. Moreover,  $P_{app}$  (B to A) had to be statistically lower ( $P < 0.05$ ;  $n = 3$ –6 monolayers) in the presence of an inhibitor to assess the specificity of an observed carrier-mediated transport. Experimental conditions were checked using the dual P-gp/BCRP substrate <sup>3</sup>H-prazosin.

### Concentration Equilibrium Assay

The concentration equilibrium assay was performed according to previous studies (21) using the same cell culture and seeding conditions as the bidirectional transport assay. The preincubation buffer was removed by aspiration and replaced in both compart-

**TABLE 1**  
Analytic Methods to Determine Concentration of Test Compounds in Incubation Buffer

Test compound	Chemical Abstract registry number	Assay 1 (ultraviolet HPLC)			Assay 2 (radioactivity counting)	
		System	λ (nm)	t <sub>R</sub> (min)	Emission	Isotope
Befloxatone	134564-82-2	Condition A	250	5.7	—	—
( <i>R,S</i> )-CGP-12177	81047-99-6	Condition B	254	2.3	—	—
Clorgyline	17780-72-2	Condition A	290	3.8	—	—
<i>R</i> -(-)-deprenyl	14611-51-9	Condition A	210	3.3	—	—
Diprenorphine	14357-78-9	Condition A	245	3.4	—	—
DPA-714	868072-17-7	Condition C	264	9.0	γ	<sup>18</sup> F
Fallypride	166173-78-0	Condition C	220	4.4	γ	<sup>18</sup> F
Flumazenil	78755-81-4	Condition D	254	1.7	—	—
2-Fluoro-A-85380	186588-98-7	Condition C	243	8.1	γ	<sup>18</sup> F
LBT-999	877467-20-4	Condition A	220	3.8	γ	<sup>18</sup> F
Loperamide	53179-11-6	Condition A	210	4.2	—	—
<i>p</i> -MPPF	155204-26-5	Condition A	254	3.9	—	—
PE2I	188680-71-9	Condition C	270	5.2	—	—
PIB	566169-93-5	Condition A	300	2.2	—	—
( <i>R,S</i> )-PK11195	85532-75-8	Condition A	254	6.0	—	—
Prazosin	19216-56-9	—	—	—	β <sup>-</sup>	Tritium
Raclopride	84225-95-6	Condition A	330	3.8	β <sup>-</sup>	Tritium
<i>R</i> -(+)-verapamil	38321-02-7	Condition A	284	5.2	—	—
WAY-100635	162760-96-5	Condition A	254	4.0	—	—

ments by the same buffer containing the test compound (5  $\mu\text{M}$ ), with or without inhibitor. The dual P-gp and BCRP substrate  $^3\text{H}$ -prazosin ( $\sim 3.7$  kBq/mL) was added to the solution as an internal positive control. The  $^{18}\text{F}$ -radiolabeled analogs of some of the screened compounds were also tested at about 11 kBq/mL when they were available. Plates were then placed at  $37^\circ\text{C}$  for 3 h under a humidified atmosphere and gentle shaking to allow polarized P-gp- or BCRP-mediated transport through the cell monolayer. The concentrations in the apical and basolateral compartments were then determined at the end of incubation.

### Analytic and $\beta^-$ or $\gamma$ -Counting Procedures

Nonradioactive compounds were assayed by ultraviolet HPLC analysis; the radioactivities of their  $\beta^-$  or  $\beta^+$  radiolabeled analogs were counted. The analytic methods used are summarized in Table 1.

A Cobra Quantum D5003 counter (Perkin-Elmer) was used for  $\gamma$ -counting, and tritium radioactivity was measured in a Tri-Carb 2250CA analyzer (Packard) and Ultima-Gold scintillation cocktail (Perkin-Elmer) 2 d later, to allow  $\beta^+$  decay when  $^{18}\text{F}$ -radiolabeled compounds were tested.

For ultraviolet HPLC, samples of the initial incubation solution, apical and basolateral compartments, were centrifuged and the supernatant injected directly onto the Alliance chromatographic system, which consisted of a Symmetry C-18 column,  $4.6 \times 150$  mm (5  $\mu\text{m}$ ), coupled to a 2996 photodiode array detector (Waters). The mobile phase flow rate was set at  $1 \text{ mL} \cdot \text{min}^{-1}$ . The separation and detection parameters of each compound are described in Table 1.

Condition A: gradient elution from  $T_{0 \text{ min}}$  (A/B = 90/10) to  $T_{5 \text{ min}}$  (A/B = 10/90) – eluent: A = 99.95/0.05 water/formic acid (v/v); B = 99.95/0.05 acetonitrile/formic acid (v/v).

Condition B: isocratic elution – eluent: 89.95/10/0.05 water/acetonitrile/formic acid (v/v/v).

Condition C: gradient elution from  $T_{0 \text{ min}}$  (A/B = 90/10) to  $T_{10 \text{ min}}$  (A/B = 10/90) – eluent: A = 99.95/0.05 water/formic acid (v/v); B = 99.95/0.05 acetonitrile/formic acid (v/v).

Condition D: isocratic elution – eluent: 64.97/34.98/0.05 acetonitrile/water/formic acid (v/v/v).

Concentration was calculated on the basis of a calibration curve (0–20  $\mu\text{M}$ ) performed for each compound, plotting ultraviolet HPLC peak area as a function of the concentration. Final concentrations in the concentration equilibrium assay are expressed as a percentage of the initial concentration  $C_0$  determined experimentally. Polarized transport was identified when the concentration in the apical compartment at the end of incubation was significantly greater than that in the basolateral compartment using unpaired 2-tailed Student  $t$  tests ( $n = 3$ –6 for each experiment). The threshold of significance was set at a  $P$  value of less than 0.05. Any polarized transport had to be abolished by P-gp or BCRP inhibitors to ensure its specificity.


## RESULTS

Bidirectional transport was assessed to determine the permeability of  $p$ -MPPF through MDCKII-MDR1 cells:  $P_{\text{app}} (\text{A to B}) = 313 \pm 15 \text{ nm} \cdot \text{s}^{-1}$  and  $P_{\text{app}} (\text{B to A}) = 248 \pm 11 \text{ nm} \cdot \text{s}^{-1}$  in the absence of inhibitor (efflux ratio =  $\sim 0.8$ ). The  $p$ -MPPF efflux ratio was not reduced by the P-gp inhibitor PSC833, in contrast to that of the typical substrate


prazosin (efflux ratio = 2.1 and 1.0, without and with inhibitor, respectively).

The functionality of the concentration equilibrium assay was checked by the time-dependent transport of prazosin through the MDR1 and BCRP cell monolayers, indicated by an increased concentration in the apical compartment and a simultaneous decrease in the basolateral compartment, which was significant after 120 min of incubation (Fig. 2), as previously reported (21). We therefore used an incubation time of 180 min (Figs. 2 and 3). The polarity of prazosin transport remained slightly significant in BCRP cells in the presence of the BCRP inhibitor fumitremorgin C, suggesting the presence of basal endogenous canine P-gp transport activity, as shown for an MDCKII clone (22).

There was no significant P-gp- or BCRP-mediated transport of CGP-12177, clorgyline, deprenyl, DPA-714, fall-ypride, flumazenil, 2-fluoro-A-85380, LBT-999,  $p$ -MPPF, PE2I, PIB, PK11195, raclopride, or WAY-100635 (Table 2). Diprenorphine, loperamide, and  $R$ -(+)-verapamil were confirmed as P-gp substrates. The concentrations of  $R$ -(+)-verapamil and loperamide were higher in compartment B than in compartment A at the end of incubation in the absence of functional P-gp, suggesting the presence of another transport system that carries them in the opposite direction to the P-gp efflux. There was significant polarized



**FIGURE 2.** Percentage  $\pm$  SD of initial concentration ( $C_0$ ) vs. time of dual P-gp and BCRP substrate prazosin in apical compartment (compartment A) and basolateral compartment (compartment B) using concentration equilibrium assay performed on MDCKII cells transfected with human *MDR1* (top) and *BCRP* (bottom) without (closed symbols) or with (open symbols) transport inhibitor. \* $P < 0.05$ . \*\*\* $P < 0.001$ .



**FIGURE 3.** Percentage  $\pm$  SD of initial concentration ( $C_0$ ) obtained in apical compartment (compartment A, white columns) and basolateral compartment (compartment B, black columns) at end of incubation after concentration equilibrium assay performed using MDCKII-MDR1 (left) and BCRP cells (right) with or without inhibitor. \* $P < 0.05$ . \*\*\* $P < 0.001$ .

TABLE 2

Transport of PET Compounds by Human P-gp and BCRP Using In Vitro Concentration Equilibrium Assay with MDCKII Cells Transfected with *MDR1* and *BCRP* Genes

Test compound	PET pharmacologic target	P-gp substrate	BCRP substrate
Prazosin	P-gp/BCRP	Yes	Yes
Befloxatone	Monoamine oxidase A	No	Yes
( <i>R,S</i> )-CGP-12177	$\beta_1/\beta_2$ -adrenoreceptor	No	No
Clorgyline	Monoamine oxidase A	No	No
R-(–)-deprenyl	Monoamine oxidase B	No	No
Diprenorphine	Opiate receptor	Yes	No
DPA-714	Peripheral benzodiazepine receptor (translocator protein 18 kDa)	No	No
Fallypride	Dopamine D <sub>2</sub> and D <sub>3</sub> receptors	No	No
Flumazenil	Central benzodiazepine receptor	No	No
2-Fluoro-A-85380	$\alpha 4\beta 2$ nicotinic acetylcholine receptor	No	No
LBT-999	Dopamine transporter	No	No
Loperamide	P-gp	Yes	No
<i>p</i> -MPPF	1A serotonin receptor	No	No
PE2I	Dopamine transporter	No	No
PIB	$\beta$ -amyloid plaques	No	No
( <i>R,S</i> )-PK11195	Peripheral benzodiazepine receptor (translocator protein 18 kDa)	No	No
Raclopride	Dopamine D <sub>2</sub> and D <sub>3</sub> receptors	No	No
R-(+)-verapamil	P-gp/Ca <sup>2+</sup> channel	Yes	No
WAY-100635	1A serotonin receptor	No	No

transport of befloxtatone through cells bearing BCRP (but not P-gp). This transport was completely inhibited by fumitremorgin C. None of the other compounds tested were BCRP substrates (Fig. 3).

## DISCUSSION

We tested several PET compounds to determine their transport by P-gp and BCRP using a sensitive, human-specific in vitro assay (Fig. 1; Table 2). Some of our findings on the role of P-gp in the transport of some PET radioligands differ from those previously published, possibly because the previous in vivo PET experiments were performed on rodents. We also suggest that the newly described BCRP is involved in the transport of some compounds.

In vitro bidirectional transport studies across epithelial cells transfected with the human *MDR1* gene are widely used for nonclinical drug studies (7). The Food and Drug Administration considers these techniques to be a reference tool for testing the transport of new chemical entities by P-gp, as species-to-species extrapolation of the interactions of compounds with P-gp is hazardous in vivo (10). The correlation between the interaction of many compounds in vitro with human *MDR1* and mouse *Mdr1a* is poor (9,23), and recently published data suggest that there are differences between rodents and humans in the transporter profiles of the brain capillary endothelial cells forming the BBB (24). Thus, a specific human model is needed to clarify the P-gp substrate status of the drugs, so as to prevent any drug–drug interaction that could occur in clinical practice and variability in the brain distribution due to variations in transporter expression. However, bidirectional transport studies

may fail to identify poor P-gp substrates, especially drugs that rapidly permeate biologic membranes (20), because the cell monolayer is exposed to a concentration gradient: molecular diffusion along this gradient should be greater than the transporter-mediated efflux. This was recently illustrated when conventional in vitro models failed to identify some antiepileptic drugs as P-gp substrates (21). In the concentration equilibrium assay, the drug is initially added at identical concentration to both sides of a polarized P-gp- or BCRP-overexpressing cell monolayer instead of being applied to either the apical or the basolateral side for studying bidirectional transport. This method allows active transport to be evaluated independently of the passive diffusion component and was shown to be more sensitive in demonstrating any carrier-mediated transport of highly permeable compounds (21). These findings justify the use of the concentration equilibrium assay to study the carrier-mediated transport of drugs with significant BBB permeability. This in vitro model also provides reliable specificity toward ABC transporter efflux. Polarized transport observed through selectively transfected *MDR1* and *BCRP* cell lines can be characterized by measuring the effect of selective reversal agents. In this work, the nonimmunosuppressive cyclosporine derivative PSC833 was used as a P-gp inhibitor because of its negligible effect on human BCRP at 5  $\mu$ M (25). In the same way, the fungal toxin fumitremorgin C (10  $\mu$ M) was chosen for its specific inhibitory effect on human BCRP (26).

The P-gp- and BCRP-mediated transport of SPECT radiopharmaceuticals such as <sup>99m</sup>Tc-sestamibi, <sup>99m</sup>Tc-tetrofosmin, <sup>99m</sup>Tc-hexamethyl-propyleneamine oxime, and <sup>123</sup>I-metaiodobenzylguanidine has been studied in vitro (27,28). However, most studies on the P-gp-mediated transport of

compounds used for PET have been performed in vivo on rodents. An extensive study on rats tested 8 PET ligands; the enhanced brain uptake of  $^{11}\text{C}$ -flumazenil and  $^{11}\text{C}$ -donepezil after P-gp inhibition with cyclosporine A suggested that there was P-gp transport for these compounds, unlike  $^{11}\text{C}$ -PK11195 (29). Similarly, three 5-hydroxytryptamine receptor 1A radioligands— $^{11}\text{C}$ -(*R*)-(-)-RWAY ( $^{11}\text{C}$ -2,3,4,5,6,7-hexahydro-1{4-[1[4-(2-methoxyphenyl)-piperazinyl]]-2-phenylbutyryl}-1H-azepine) (30),  $^{18}\text{F}$ -MPPF (31), and  $^{11}\text{C}$ -WAY100635 (32)—were identified as P-gp substrates in rodents. However, the results obtained in monkeys were different;  $^{11}\text{C}$ -(*R*)-(-)-RWAY was not found to be a P-gp substrate after inhibition with tariquidar (33). Studies with the P-gp inhibitor DCPQ ((2*R*)-anti-5-{3-[4-(10,11-dichloromethanodibenzo-suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy} quinoline trihydrochloride) showed that P-gp had no effect on the brain distribution of the cerebral cannabinoid receptor radioligand  $^{11}\text{C}$ -MePPEP in monkeys (34). However, the results of these in vivo inhibition studies must be interpreted carefully because the P-gp structure has multiple binding sites that have a significant impact on drug transport properties (35). Thus, P-gp should not be considered a transporter with a single site of broad substrate specificity that could simply be “switched off” by modulators. Interactions between inhibitor and substrate molecules involve complex allosteric interactions at distinct binding sites (36). Consequently, a lack of increase in brain uptake obtained with a P-gp modulator does not necessarily mean that there is no P-gp-mediated transport.

Some newly developed central nervous system radiotracers designed for histamine  $\text{H}_3$  receptor mapping were recently tested in an in vitro model of human P-gp to ensure that they did not interact with P-gp at a preclinical stage (37). However, there is a real need to determine how the compounds used for PET are transported by human P-gp and BCRP (6). Some of the compounds we have tested have been evaluated in conventional bidirectional transport studies. These studies showed that verapamil is a poorer P-gp substrate (efflux ratio of 1.7) than loperamide (efflux ratio of 9.9) (20,38). They also revealed that deprenyl and flumazenil are not P-gp substrates. Our concentration equilibrium assay studies confirmed these previous results, showing that deprenyl and flumazenil are not transported by human P-gp or BCRP. These data differ from those obtained in vivo in rats by Ishiwata (29), suggesting that P-gp influences the brain uptake of flumazenil. This difference could be due to interspecies variations in the P-gp-mediated transport of flumazenil. *p*-MPPF and WAY-100635 are also considered to be P-gp substrates (increased uptake after P-gp inhibition) in rodents. However, to our knowledge, the transport of *p*-MPPF by human P-gp has never been evaluated either in vitro or in vivo. Our results obtained using the conventional bidirectional assay and the more sensitive concentration equilibrium assay suggest that *p*-MPPF is not transported by human P-gp. Likewise, WAY-100635 is not influenced by human P-gp in vitro.

The respective transport of verapamil enantiomers has already been described and has shown no evidence of stereoselectivity (39). However,  $^{11}\text{C}$ -(*R*)-verapamil, which is less metabolized and has a lower affinity for the calcium channel, is usually preferred over the racemate for P-gp activity imaging. In the same way, some screened compounds are preferentially—for PET purposes—used as enantiomers instead of racemate (i.e., (*R*)-PK11195 and (*S*)-CGP-12177). Racemate solutions were tested in this screening for these 2 compounds. If an active transport has been found, a further investigation would have been undertaken to evidence a putative enantioselectivity, as described for (*R*)- and (*S*)-methadone (19). However, our results show that none of the PK11195 or CGP-12177 enantiomers were transported by P-gp or BCRP, which gives reliable information for whenever the racemic mixture or an enantiomer is used for PET.

Diprenorphine was found as a P-gp substrate with the concentration equilibrium assay, whereas conventional bidirectional studies failed to reveal this transport using Caco-2 cells (40). The polarized transport of diprenorphine through Caco-2 cells (efflux ratio,  $\sim 2$ ) was attributed to a transporter other than P-gp by Hassan et al. (40), because it was not inhibited by the dual P-gp/BCRP inhibitor GF120918 (*N*-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide) and verapamil. However, we found no polarized transport of diprenorphine in BCRP cells, in contrast to MDR1 cells, where it is inhibited by PSC833, suggesting a reliable P-gp transport specificity (Fig. 3).

Our findings raise the question of whether bias is introduced in vivo by the ABC protein-mediated efflux of PET tracers when used on humans (6). Recent publications suggest that Alzheimer disease could be linked to a loss of P-gp function at the BBB (1,5).  $^{11}\text{C}$ -PIB is a useful PET radiopharmaceutical for imaging A $\beta$  deposits in Alzheimer disease. We find that PIB is not transported by P-gp or BCRP. Thus, the cerebral accumulation of PIB is probably not influenced by any gradual change in P-gp-mediated efflux. The consequence of inhibiting P-gp on the  $^{11}\text{C}$ -diprenorphine distribution volume remains to be evaluated in vivo. Hume et al. suggested that this could be a factor influencing variations in the brain uptake of  $^{11}\text{C}$ -diprenorphine (41). (*R,S*)-PK11195 has been found to be a potent inhibitor of the human P-gp and BCRP on multidrug resistant cells in vitro (42). However, (*R,S*)-PK11195 is not transported by P-gp in vitro (42) or in vivo (29), as confirmed by the present in vitro study.

We find that the monoamine oxidase A antagonist befoxatone is specifically transported by human BCRP and not by P-gp. Therefore, radiolabeled  $^{11}\text{C}$ -befloxatone could be a candidate for estimating the specific involvement of BCRP at the BBB. Further studies should focus on the brain distribution of befoxatone in the presence of a BCRP inhibitor in vivo. The bias introduced by the BCRP-mediated

transport on the brain kinetic parameters of  $^{11}\text{C}$ -befloxatone could be evaluated in baboons and humans using previously described quantification methods (43).

## CONCLUSION

We have used a specific, sensitive *in vitro* model to show that several PET compounds, including *p*-MPPF, WAY-100635, and flumazenil, are not transported by human P-gp or BCRP. Some of these results do not agree with data obtained in rodents, showing the importance of using specific human *in vitro* models. The impact of BCRP and P-gp on the kinetics of their respective substrates  $^{11}\text{C}$ -befloxatone and  $^{11}\text{C}$ -diprenorphine remains to be established *in vivo* to evaluate the influence of this active transport on the quantification performed in preclinical and clinical protocols. The method described here can readily be used to screen new-compound transport by P-gp or BCRP, even before any radiolabeling. The method can also be useful for identifying new radiotracer candidates designed to interact specifically with these 2 major transporters.

## ACKNOWLEDGMENTS

This work was supported by a grant from the CEA (Commissariat à l'énergie atomique et aux énergies alternatives) and the AP-HP (Assistance Publique-Hôpitaux de Paris). The English text was edited by Dr. Owen Parkes.

## REFERENCES

- Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. *Neurobiol Dis.* 2009;37:13–28.
- Levrin O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. *Hum Mol Genet.* 2008;17:2219–2227.
- Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. *Clin Pharmacol Ther.* 2007;81:539–546.
- Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. *Pharmacol Ther.* 2006;112:457–473.
- Kannan P, John C, Zoghbi SS, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and *in vivo* applications. *Clin Pharmacol Ther.* 2009;86:368–377.
- Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. *Trends Pharmacol Sci.* 2009;30:431–440.
- Giacomini KM, Huang S, Tweedie DJ, et al. Membrane transporters in drug development. *Nat Rev Drug Discov.* 2010;9:215–236.
- Cattelotte J, Tournier N, Rizzo-Padoin N, Schinkel AH, Scherrmann JM, Cisternino S. Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of  $^{99\text{m}}\text{Tc}$  sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2. *J Neurochem.* 2009;108:767–775.
- Takeuchi T, Yoshitomi S, Higuchi T, et al. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. *Pharm Res.* 2006;23:1460–1472.
- Syvänen S, Lindhe O, Palmer M, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. *Drug Metab Dispos.* 2009;37:635–643.
- Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. *Clin Pharmacol Ther.* 2005;77:503–514.
- Kreisl WC, Liow JS, Kimura N, et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer  $^{11}\text{C}$ -N-desmethyl-loperamide. *J Nucl Med.* 2010;51:559–566.
- Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. *Adv Drug Deliv Rev.* 2009;61:14–25.
- Damont A, Hinnen F, Kuhnast B, et al. Radiosynthesis of [ $^{18}\text{F}$ ]DPA-714, a selective radioligand for imaging the translocator protein (18 kDa) with PET. *J Labelled Comp Radiopharm.* 2008;51:286–292.
- Dollé F, Dolci L, Valette H, et al. Synthesis and nicotinic acetylcholine receptor *in vivo* binding properties of 2-fluoro-3-[2(S)-2-azetidylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. *J Med Chem.* 1999;42:2251–2259.
- Dollé F, Helfenbein J, Hinnen F, et al. One-step radiosynthesis of [ $^{18}\text{F}$ ]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. *J Labelled Comp Radiopharm.* 2007;50:716–723.
- Emond P, Garreau L, Chalou S, et al. Synthesis and ligand binding of nortropine derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropine and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropine—new high-affinity and selective compounds for the dopamine transporter. *J Med Chem.* 1997;40:1366–1372.
- Kuhnast B, Hinnen F, Dollé F. Production of [ $^{18}\text{F}$ ]fallypride on a TRACERLab FX-FN synthesizer [abstract]. *J Labelled Comp Radiopharm.* 2009;52(suppl 1): S286.
- Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). *Int J Neuropsychopharmacol.* 2010;13:905–915.
- Mahar Doan KM, Humphreys JE, Webster LO, et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. *J Pharmacol Exp Ther.* 2002;303:1029–1037.
- Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. *Neuropharmacology.* 2008;55:1364–1375.
- Goh LB, Spears KJ, Yao D, et al. Endogenous drug transporters in *in vitro* and *in vivo* models for the prediction of drug disposition in man. *Biochem Pharmacol.* 2002;64:1569.
- Suzuyama N, Katoh M, Takeuchi T, et al. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. *J Pharm Sci.* 2007;96:1609–1618.
- Dauchy S, Dutheil F, Weaver RJ, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. *J Neurochem.* 2008;107:1518–1528.
- Pavek P, Merino G, Wagenaar E, et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. *J Pharmacol Exp Ther.* 2005;312:144–152.
- Robey RW, Steadman K, Polgar O, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. *Cancer Res.* 2004;64:1242–1246.
- Tournier N, Andre P, Blondeel S, et al. Ibogaine labeling with  $^{99\text{m}}\text{Tc}$ -tricarbonyl: synthesis and transport at the mouse blood-brain barrier. *J Pharm Sci.* 2009; 98:4650–4660.
- Kiyono Y, Yamashita T, Doi H, et al. Is MIBG a substrate of P-glycoprotein? *Eur J Nucl Med Mol Imaging.* 2007;34:448–452.
- Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. *In vivo* evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. *J Nucl Med.* 2007;48:81–87.
- Liow JS, Lu S, McCarron JA, et al. Effect of a P-glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5-HT $_{1A}$  receptor radioligand, [ $^{11}\text{C}$ ](R)-(-)-RWAY. *Synapse.* 2007;61:96–105.
- Lacan G, Plenevaux A, Rubins DJ, et al. Cyclosporine, a P-glycoprotein modulator, increases [ $^{18}\text{F}$ ]MPPF uptake in rat brain and peripheral tissues: microPET and *ex vivo* studies. *Eur J Nucl Med Mol Imaging.* 2008;35:2256–2266.
- Elsinga PH, Hendrikse NH, Bart J, van Waarde A, Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. *Mol Imaging Biol.* 2005;7:37–44.
- Yasuno F, Zoghbi SS, McCarron JA, et al. Quantification of serotonin 5-HT $_{1A}$  receptors in monkey brain with [ $^{11}\text{C}$ ](R)-(-)-RWAY. *Synapse.* 2006;60:510–520.
- Yasuno F, Brown AK, Zoghbi SS, et al. The PET radioligand [ $^{11}\text{C}$ ]MePPEP binds reversibly and with high specific signal to cannabinoid CB $_1$  receptors in nonhuman primate brain. *Neuropsychopharmacology.* 2008;33:259–269.
- Crowley E, Callaghan R. Multidrug efflux pumps: drug binding: gates or cavity? *FEBS J.* 2010;277:530–539.
- Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. *Mol Pharmacol.* 2000;58:624–632.
- Hamill TG, Sato N, Jitsuoka M, et al. Inverse agonist histamine H $_3$  receptor PET tracers labelled with carbon-11 or fluorine-18. *Synapse.* 2009;63:1122–1132.



38. Varma MV, Sateesh K, Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. *Mol Pharm*. 2005;2:12–21.
39. Luurtsema G, Molthoff CF, Windhorst AD, et al. (R)- and (S)-[<sup>11</sup>C]verapamil as PET-tracers for measuring P-glycoprotein function: *in vitro* and *in vivo* evaluation. *Nucl Med Biol*. 2003;30:747–751.
40. Hassan HE, Myers AL, Coop A, Eddington ND. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: *in vitro* and *in vivo* evaluation. *J Pharm Sci*. 2009;98:4928–4940.
41. Hume SP, Lingford-Hughes AR, Nataf V, et al. Low sensitivity of the positron emission tomography ligand [<sup>11</sup>C]diprenorphine to agonist opiates. *J Pharmacol Exp Ther*. 2007;322:661–667.
42. Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbaum FR, Banker DE. PK11195, a peripheral benzodiazepine receptor (PBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a PBR-independent, direct transporter-modulating mechanism. *Blood*. 2005;106:3584–3593.
43. Bottlaender M, Valette H, Delforge J, et al. *In vivo* quantification of monoamine oxidase A in baboon brain: a PET study using [<sup>11</sup>C]befloxatone and the multi-injection approach. *J Cereb Blood Flow Metab*. 2010;30:792–800.